Previous close | 17.63 |
Open | 17.63 |
Bid | 0.00 x 0 |
Ask | 0.00 x 0 |
Day's range | 17.63 - 17.63 |
52-week range | 15.78 - 22.67 |
Volume | |
Avg. volume | 454 |
Market cap | 9.478B |
Beta (5Y monthly) | 0.20 |
PE ratio (TTM) | 25.55 |
EPS (TTM) | 0.69 |
Earnings date | 07 May 2024 |
Forward dividend & yield | 0.39 (2.23%) |
Ex-dividend date | 27 Jun 2024 |
1y target est | N/A |
TOKYO, April 15, 2024--On Friday, 12th April, 2024, Professor Julia Scarisbrick of University of Birmingham presented interim findings from the Kyowa Kirin, Inc. (Kyowa Kirin, TSA: 4151)-sponsored study, "Real-World Observational Study of Mogamulizumab in Adult Patients with Mycosis Fungoides and Sézary Syndrome (PROSPER)", a prospective observational study evaluating the real-world impact of mogamulizumab on disease symptoms and health-related quality of life (HRQoL) in patients with these subt
Kyowa Kirin Co., Ltd. (TSE: 4151) a Japan-based global specialty pharmaceutical company (J-GSP) creating innovative medical solutions utilizing the latest biotechnology, today announced that pre-clinical data of tivozanib (KHK-4951), an investigational product, assessing the ocular pharmacokinetics of a novel tivozanib eye drop for neovascular age-related macular degeneration (nAMD), will be presented at the upcoming Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting to b
Kyowa Kirin Co., Ltd. (TSE: 4151) today announced that post-hoc analysis data from the Phase 2b study of rocatinlimab (AMG 451/KHK4083), an investigational product in patients with moderate-to-severe atopic dermatitis (msAD), will be presented at the American Academy of Dermatology (AAD) 2024 Annual Meeting to be held in San Diego from March 8-12, 2024.